Sequoia Financial Advisors LLC boosted its position in shares of Solventum Co. (NYSE:SOLV – Free Report) by 8.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,737 shares of the company’s stock after purchasing an additional 441 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Solventum were worth $400,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Copeland Capital Management LLC bought a new stake in shares of Solventum in the third quarter valued at about $26,000. Mather Group LLC. bought a new stake in shares of Solventum in the 3rd quarter valued at about $27,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Solventum in the 1st quarter worth approximately $30,000. Hollencrest Capital Management bought a new position in shares of Solventum during the second quarter valued at approximately $25,000. Finally, Deseret Mutual Benefit Administrators purchased a new position in Solventum during the second quarter valued at approximately $25,000.
Solventum Stock Down 0.0 %
Shares of Solventum stock opened at $73.19 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31. The stock’s 50 day simple moving average is $67.58 and its 200-day simple moving average is $61.26.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on SOLV shares. Morgan Stanley lowered their target price on Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. The Goldman Sachs Group upped their price objective on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Piper Sandler initiated coverage on Solventum in a research note on Monday, October 7th. They issued a “neutral” rating and a $71.00 target price on the stock. Wolfe Research assumed coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Finally, Stifel Nicolaus began coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $64.33.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- How to invest in marijuana stocks in 7 stepsĀ
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Calculate Return on Investment (ROI)
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Roth IRA Calculator: Calculate Your Potential Returns
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.